FDA 510(k) Strategy & Intended Use Consulting

In an FDA 510(k), intended use describes the general purpose of the device, including what it does, who it is for, and the clinical setting or condition it addresses. It is central to substantial equivalence because FDA compares your intended use to the predicate device. If the wording is too broad, inconsistent, or unsupported by evidence, it can trigger major review questions or derail the submission.

FDA 510(k) rules require a manufacturer to show that a device is substantially equivalent to a legally marketed predicate device. The submission must include device description, intended use, indications for use, comparison to the predicate, performance testing, labeling, and other applicable technical sections. FDA also expects the submission format, evidence quality, and claims to align with current guidance and device-specific requirements.

Intended use is one of the first things FDA evaluates because it shapes predicate selection, testing strategy, labeling, and the substantial equivalence argument. If your intended use differs materially from the predicate, FDA may determine the device is not appropriate for the 510(k) pathway. Clear, precise language helps support review efficiency and reduces the risk of avoidable Additional Information requests.

A strong predicate is selected by analyzing intended use, indications, technological characteristics, classification regulation, product code, and performance expectations. The goal is not simply to find a similar device, but to identify one that supports a credible substantial equivalence argument. A poor predicate choice can create unnecessary comparison weaknesses, increase reviewer concerns, and complicate the entire submission strategy.

510(k) strategy should begin well before submission drafting, ideally during development planning or design verification planning. Early strategy work helps define the likely pathway, predicate approach, testing needs, labeling boundaries, and documentation gaps before they become expensive delays. Starting early also improves coordination across regulatory, engineering, clinical, and quality teams so the submission package is built intentionally rather than assembled reactively.

No, many 510(k) submissions rely on bench, software, biocompatibility, sterility, EMC, or other non-clinical testing to support substantial equivalence. However, some devices do require clinical evidence depending on their technology, claims, risk profile, or the limitations of available predicates. A proper regulatory strategy evaluates this early so the evidence plan is proportionate, scientifically justified, and aligned with FDA expectations.

An Additional Information request means FDA needs clarification, missing evidence, or stronger justification before continuing review. The response should address each deficiency directly, using organized technical rationale, updated documents, and complete supporting data where needed. A weak or incomplete response can lead to further delays, another round of questions, or submission withdrawal, so structured response planning is critical.

Before submission, manufacturers should review intended use and indications, predicate rationale, device description, labeling consistency, risk management documentation, test reports, software records if applicable, and overall traceability across the package. A readiness assessment should also confirm that the submission aligns with current FDA guidance and eSTAR expectations. This pre-submission review helps identify gaps before they become formal deficiencies.